DRAFT   CONFIDENTIAL  
 9 March 2014  i Multi -Center Evaluation of Clinical Outcomes of Pulse 
Widths <500ùúáùúásec and >1000ùúáùúásec During a Temporary 
Spi[INVESTIGATOR_54178]:  Multi -Center Evaluation of Clinical Outcomes of Pulse Widths 
<500ùúáùúásec and >1000ùúáùúásec During a Temporary Spi[INVESTIGATOR_54179]:  TBD  
Device:  Nuvectra¬Æ Algovita¬Æ Spi[INVESTIGATOR_54180]:  The Ohio Pain Clinic  
[ADDRESS_57934]:  Amol Soin, MD  
[ADDRESS_57935] ‚Ä®              
Dayton, OH [ZIP_CODE]             
[EMAIL_948] 
 
Study Site s: TBD  
 
Medical Monitor:  Erin Dewenter, RN                         
Ohio Pain Clinic                        
[ADDRESS_57936]        
Dayton, OH [ZIP_CODE] 
Date of Protocol:  TBD  
 
Confidentiality Statement  
The confidential information in this document is provided to you as an investigator or consultant for review by [CONTACT_10825], your sta ff, and the applicable 
Institutional Review Board.  Your acceptance of this document constitutes agreement that you will not disclo se the information contained herein 
to others without written authorization from   . 
 
  
DRAFT   CONFIDENTIAL  
  ii Protocol Synopsis  
Sponsor Contact 
[CONTACT_54211], MD  
[ADDRESS_57937] of pulse widths <500 ¬µsec and 
>[ADDRESS_57938] back and/or leg pain, have been evaluated 
as a candidate for SCS and have agreed to undergo a tempo rary SCS trial using 
the Algovita¬Æ system with percutaneous leads. Each subject will be followed 
during the trial period of approximately 7+/-[ADDRESS_57939] has completed the trial period and 
exited. The expected enrollmen t period for this study is approximately six 
months. After exit from the clinical study, subjects will continue to be followed 
by [CONTACT_54212]. All device and procedure -related AEs will be 
collected and reported per the study protocol. 
Primary 
Effectiveness 
Objective  Compare the change in the patient defined pain coverage map from baseline to 
the end of the 7+/-2 day trial. 
Secondary 
Effectiveness Objectives  Secondary measures of therapy effectiveness will include:  
‚Ä¢ Compare the change fr om baseline of pain scores between the two study 
arms. Pain scores are obtained using the Numeric Rating Score (NRS) 
administered at baseline and after completion of each arm of the study.  
‚Ä¢ Paresthesia distribution: At end of each arm, subjects will be aske d to 
complete a diagram that shows distribution of paresthesia.  
‚Ä¢ At the end of the trial period, subjects will be asked to select their favorite 
program. 
‚Ä¢ At the end of the trial period, subjects will be asked to rate the quality of 
the pain relief achieved during the trial (from either arm) using the 
following scale ; Excellent, Very Good, Good, Fair or Poor . 
‚Ä¢ At the end of the trial period, subjects will be asked to rate their overall 
satisfaction with the pain relief achieved during the trial (from either arm) 
using the following scale: Very Satisfied, Satisfied, Neither Satisfied nor 
Unsatisfied, Unsatisfied,  or Very Unsatisfied . 
              
  Secondary 
Safety Objectives  Secondary measures of therapy safety will include:  
‚Ä¢ Rate of device- related and/or procedure -related AEs from the Trial 
procedure through study completion. 
DRAFT   CONFIDENTIAL  
  iii Study Procedures  After the subject has consented to the study, he or she will be enrolled in the 
clinical study and undergo a baseline evaluation. The patient will then be 
randomly assigned to arm one (pulse with <500 ¬µsec) or arm two (pulse width 
>1000 ¬µsec) and undergo an Algovita¬Æ trial procedures. Following the trial 
procedure, the subject‚Äôs EPG will be set to the appropriate pulse width, based on 
the arm assigned, and then programmed to achieve optimal pain relief. For the 
next three days, the subject will evaluate pain relief generated by [CONTACT_941] 1st assigned 
program (arms).  
After [ADDRESS_57940] is exited from the study, he or she will be followed  
by [CONTACT_54213]. The data collection requirements are 
listed below.  
Enrollment:  
‚Ä¢ Informed consent signed 
‚Ä¢ Confirmation of study eligibility  
Baseline evaluation: 
‚Ä¢ Record pain ratings and pain map 
‚Ä¢ Relevant medical history  
‚Ä¢ Physical exami nation 
‚Ä¢ Brief Pain Inventory 
‚Ä¢ Demographics 
After the lead implantation: 
‚Ä¢ Implant procedure 
‚Ä¢ Document SCS products & lead configuration, electrode position and 
programmed parameters  
4 and 7 day (+/‚Äì 2) Post -Implantation:  
‚Ä¢ Record pain map data  
‚Ä¢ Record pain rating for current arm  
‚Ä¢ Record paresthesia and pain map for current arm  
‚Ä¢ Document AEs 
‚Ä¢ Program subject with next arm parameters and document  
Study Exit  
‚Ä¢ Record pain map data  
‚Ä¢ Record pain rating for current arm  
‚Ä¢ Record paresthesia and pain map for current arm  
‚Ä¢ Record program preference  
‚Ä¢ Record satisfaction and pain relief from each program  
‚Ä¢ Document study exit reason & AEs 
DRAFT   CONFIDENTIAL  
  iv  
TIME AND EVENTS SCHEDULE  
 
 
Assessments and Data Collection  
Enrollment  
Baseline  
After Implant  
Follow -up 
Visits  
 
 
 Study Exit  
‚Ä¢ Eligibility confirmation  ‚úì     
‚Ä¢ Medical history  
‚Ä¢ Physical exam  ‚úì     
‚Ä¢ Informed consent  ‚úì     
‚Ä¢ Record demographics  
‚Ä¢ Brief Pain Inventory 
‚Ä¢ Record pain map   ‚úì 
‚úì 
‚úì    
‚Ä¢ Implant and system information    ‚úì   
‚Ä¢ Record paresthesia and pain map for 
current arm  
‚Ä¢ Record pain rating for current arm  
‚Ä¢ Document any AEs   
 
‚úì 
‚úì  
 ‚úì 
‚úì ‚úì 
 ‚úì 
‚úì 
 
 ‚úì 
 ‚úì 
‚úì ‚úì 
 ‚úì 
‚úì 
‚Ä¢ Record subject program preference  
‚Ä¢ Record subject satisfaction and pain 
relief from each program  
‚Ä¢ Document study exit reason & any AEs     ‚úì 
‚úì 
 
‚úì 
 
FLOWCHART  
 
PROTOCOL HISTORY OF CHANGE  
TBD  Original issue  
  

DRAFT   CONFIDENTIAL  
  v Table of Contents  
 
Page  
Protocol Title  ..................................................................................................................................... i 
Protocol Synopsis  ............................................................................................................................. ii 
Protocol History of Change/ Summary of Bibliography Studies  .................................................... vi 
List of Abbreviations and Definitions  ...............................................................................................x 
1.0 INTRODUCTION ..............................................................................................................8  
2.0 OBJECTIVES  ................................................................................................................... 10 
2.1 Primary Objective  ............................................................................................... 10 
2.2 Secondary Objectives  ......................................................................................... 10 
3.0 REGULATORY CLASSIFICATION  .............................................................................. 11 
4.0 DEVICE  ............................................................................................................................ 11 
4.1 ALGOVITA¬Æ SPI[INVESTIGATOR_54181] ............................. [ADDRESS_57941] Screening Procedure ................................................................ 17 
10.1.2  Informed Consent  ................................................................................. 17 
10.1.3  BASELINE VISIT  ............................................................................... 18 
10.1.4  IMPLANT  ............................................................................................ 18 
10.1.5  FOLLOW -UP VISITS .......................................................................... 18 
10.1.6  STUDY EXIT  ....................................................................................... 18 
11.0 ADVERSE EVENT REPORTING  ................................................................................... 20 
11.1 ADVERSE EVENTS  .......................................................................................... 20 
11.2 ANTICIPATED ADVERSE DEVICE EFFECTS  ............................................. 20 
11.3 UNANTICIPATED ADVERSE DEVICE EFFECTS  ........................................ 21 
12.0 STATISTICS  .................................................................................................................... 22 
12.1 Study Population  ................................................................................................. 22 
12.2 Safety Analysis  ................................................................................................... 22 
13.0 ETHICS  ............................................................................................................................ 23 
13.1 Medical Ethics Committee ( IRB ) Review  ........................................................ [ADDRESS_57942] of the Study  .............................................................................. 23 
13.3 Patient Information and Consent  ........................................................................ 23 
DRAFT   CONFIDENTIAL  
  vi 14.0 STUDY ADMINISTRATION .......................................................................................... 24 
14.1 Study Initiation  ................................................................................................... 24 
14.2 Clinical Supplies  ................................................................................................. 24 
14.3 Case Report Forms (CRFs)  ................................................................................. [ADDRESS_57943] of Abbreviations and Definitions  
 
Abbreviation/Term  Definition  
ADE:   Adverse Device Event  
AE:  Adverse Event  
CIP:  Clinical Investigational Plan  
CRF:  Case Report Form  
CTA:  Clinical Trial Agreement  
FDA:  Food and Drug Administration  
GCP:   Good Clinical Practices  
ICF:   Informed Consent Form 
ICH:   Inter national Conference on Harmonization 
IRB:  Institutional Review Board  
ISO:   International Organization for Standardization 
NRS:  Numeric Rating Scale  
PW:  Pulse Width  
SADE:  Serious Adverse Device Effect  
SCS:  Spi[INVESTIGATOR_54182]:  Standard of Care 
UADE:  Unanticipated Adverse Device Effect  
[LOCATION_003]DE:  Unanticipated Serious Adverse Device Effect  
¬µsec:  Micro Second 
VAS:  Visual Analog Scale 
  
 
 
  
 
DRAFT   CONFIDENTIAL  
  8 1.0 INTRODUCTION  
Patients with chronic intractable pain of the trunk and/or limbs are typi[INVESTIGATOR_54183] a continuum 
with less invasive therapi[INVESTIGATOR_54184]. Established, non -surgical treatment options include, 
but are not limited to, oral medications, physical therapy, TENS, acupuncture, nerve blocks, 
radiofrequency ablation and other options based on clinical judgment. The surgical treatment options for these patients include surgery of the spi[INVESTIGATOR_050], sympathectomy, intrathecal drug pumps, 
and spi[INVESTIGATOR_54185] (SCS) systems
i. 
 An advantage of a SCS system is that it is a reversible and nondestructive treatment option. The 
main principle of SCS therapy is pain suppression via the delivery of electrical signals to the spi[INVESTIGATOR_54186]. An implantable pulse generator 
(IPG) is implanted under the skin, typi[INVESTIGATOR_54187], to generate mild electrical signals. The electrical signals typi[INVESTIGATOR_54188]. The IPG is programmed to deliver the electrical signals in a therape utic manner and 
is then activated by [CONTACT_54214]. SCS therapy treatment is deemed successful if there is a 50% reduction in pain as measured by a numeric rating 
scale or visual analog scale. The most common u se of SCS therapy is for failed back surgery 
syndrome (FBSS) that affects up to 40% of patients who undergo spi[INVESTIGATOR_54189] v. 
 A candidate for SCS therapy is first tested by [CONTACT_54215] a trial procedure in which a temporary 
lead is implanted in the epi[INVESTIGATOR_54190] (EPG). A temporary trial typi[INVESTIGATOR_31228] [ADDRESS_57944] increased safety, 
efficacy and longevity of the therapy. 
 
The Algovita¬Æ SCS System is similar in design and performance to newer SCS systems from other medical device companies. The FDA approved Algovita¬Æ system has many advanced features 
including the ability to better control the shape of the elect rical pulse. One such feature is a longer 
pulse width range than the other systems on the market. Pulse width determines how long an electrical pulse is activated. A longer pulse width is not associated with any safety concerns as 
determined by [CONTACT_1622]. The intent and justification for this study is to understand if a longer pulse 
width provides better outcomes to patients.  
 Although the effects of pulse width are mentioned in many SCS investigations, it has been the 
primary focus of very few studies. Several decades ago, research was conducted into the technical 
aspects of SCS, including PW. In a study of SCS, Jobling showed that different patients required 
widely varying amplitudes of stimulation and concluded that [ADDRESS_57945] been anecdotally 
described as achieving better pain -paresthesia overlap and comfort for the patient, thus potentially 
more effective at relieving painviii.  
DRAFT   CONFIDENTIAL  
  9  
The introduction and widespread adoption of rechargeable IPGs for SCS has diminished the 
importance of energy efficient programming to prolong time between revision surgeries and resulted in longer pulse width settings in these systems. Gould and Bradley reported in a 
retrospective analysis of patient -preferred programs that over 50% of the programs used PWs in 
excess of 450 Œºs
ix. Yearwood et al. showed that 10/19 patients had greater coverage, and 8/19 
patients displayed ‚Äúcaudal shift‚Äù of paresthesia coverage with increased PWx. A mathematical 
model of electrical field and neural activation in SCS has shown good agreement with clinical data 
that a longer PW is associated with increased paresthesia coverage and a shift of the paresthesia 
coverage caudallyxi. 
 
Investigation into the clinical and technical effects of PWs may be important in the continued effort 
to more fully understand the mechanisms of SCS. In other neurostimulation applications, varied 
PW has been shown to provide large and small fiber neural selectivity, where shorter PWs 
maximized the difference between large and small fiber thresholdsxii. With advances in SCS 
technology, particularly rechargeable IPGs, patients are now being offered a wider range of parameters to treat their pain. In particular, P W programming ranges of the Algovita¬Æ system can 
be programmed up to 1500 Œºsec).  
 
DRAFT   CONFIDENTIAL  
  [ADDRESS_57946] of conventional pulse widths <500 ¬µsec and pulse widths >1000 ¬µsec on 
clinical outcomes during temporary trial as measured by [CONTACT_54216] . 
 
2.2 Secondary Objectives  
Secondary measures of therapy effectiveness will include:  
1. To evaluate the effect of conventional pulse widths <500¬µsec and pulse widths 
>1000¬µsec on clinical outcomes during temporary trial as measured by [CONTACT_54217]. 
2. At end of each arm, subjects will be asked to complete a diagram that shows distribution of paresthesia.  
3. At the end of the trial period, subje cts will be asked to select their favorite program.  
4. At the end of the trial period, subjects will be asked to rate the quality of the pain relief 
achieved during the trial (from either arm) using the following scale ; Excellent, Very 
Good, Good, Fair or Poor  
5. At the end of the trial period, subjects will be asked to rate their overall satisfaction with the pain relief achieved during the trial (from either arm) using the following scale; Very 
Satisfied, Satisfied, Neit her Satisfied nor Unsatisfied, Unsatisfied or Very Unsatisfied 
6. Number of patients who achieved ‚â• 50% pain relief during the trial (from either arm) 
7. Rate of device-related and/or procedure-related AEs from SCS implant through study 
completion or study exit. 
 
DRAFT   CONFIDENTIAL  
  11 3.0 DEVICE 
 
3.1 ALGOVITA¬Æ SPI[INVESTIGATOR_54191]¬Æ SCS System manufactured by [CONTACT_54218]¬Æ Corporation (Plano, [LOCATION_007]). The materials, dimensions, method of construction, indications for use, and principles of operation of the Algovita¬Æ SCS system components are the same or functionally similar to the FDA -approved and CE marked products distributed 
by [CONTACT_13735], Abbott (St. Jude), and [LOCATION_011] Scientific.  The Algovita¬Æ SCS system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.  The devices used for this  study will be sourced through normal commercial 
channels from Nuvectra¬Æ and will not be supplied by [CONTACT_1034].  
3.2 REGULATORY CLASSIFICATION  
The Algovita¬Æ SCS System received CE Mark in Europe on 14 June 2014 and FDA (PMA) approval in the US on [ADDRESS_57947] ba ck and/or leg pain, have been identified 
as a candidate for SCS and have agreed to undergo a temporary SCS trial using the Algovita¬Æ system with percutaneous leads. Each subject will be followed during the trial period of approximately [ADDRESS_57948] has completed the trial period or is exited. 
The expected enrollment period for this study is approximately three months. After exit from the clinical study, subjects will continue to be followed by [CONTACT_54212]. All device and procedure -related AEs will be collected and reported 
per the study protocol. 
4.1 OVERVIEW OF DATA COLLECTION AT STUDY 
VISITS  
 
 
Assessments and Data Collection  
Enrollment  
Baseline  
After Implant  
Follow -up 
Visits  
 
 
 
Study Exit  
‚Ä¢ Eligibility confirmation  ‚úì     
‚Ä¢ Medical history  
‚Ä¢ Physical exam  ‚úì     
‚Ä¢ Informed consent  ‚úì     
‚Ä¢ Record demographics  
‚Ä¢ Brief Pain Inventory 
‚Ä¢ Record pain map   ‚úì 
‚úì 
‚úì    
‚Ä¢ Implant and system information    ‚úì   
‚Ä¢ Record paresthesia and pain map for 
current arm  
‚Ä¢ Record pain rating for current arm  
‚Ä¢ Document any AEs   
 
‚úì 
‚úì  
 
‚úì 
‚úì ‚úì 
 
‚úì 
‚úì 
 
 ‚úì 
 
‚úì 
‚úì ‚úì 
 
‚úì 
‚úì 
‚Ä¢ Record subject program preference  
‚Ä¢ Record subject satisfaction and pain 
relief from each program  
‚Ä¢ Document study exit reason & any 
AEs     ‚úì 
‚úì 
 
‚úì 
    Figure 4.1 Study Flowchart 
DRAFT   CONFIDENTIAL  
  13 5.0 ENDPOINTS  
The endpoints of the study are focused on collecting data to determine clinical 
outcomes of Pulse Widths >1000¬µseccompared to Pulse Widths <500¬µsecduring an SCS trial. Safety data will also be collected at all visits. Data will be collected using: ‚Ä¢ Patient generated Pain Maps  
‚Ä¢ The NRS to assess pain levels  
‚Ä¢ Questionnaires to assess pain coverage, program preference, overall satisfaction of the trial and AEs  
 
5.1 PRIMARY EFFECTIVENESS ENDPOINT  
The primary effectiveness endpoint is defined as the percent reduction from 
baseline in targeted patient generated pain map coverage between the two arms . 
 
5.2 SECONDARY ENDPOINTS  
Endpoints for secondary measures of therapy effectiveness: 
‚Ä¢ To evaluate the effect of conventional pulse widths and pulse widths 
>1000¬µsecon clinical outcomes during temporary trial as measured by [CONTACT_54219]. 
‚Ä¢ Comparison of paresthesia overlap of pain between each arm as evaluated by [CONTACT_54220] (coverage)  
‚Ä¢ Patient preference for pulse widths >1000¬µsecor <500 ¬µS 
‚Ä¢ Patient satisfaction  for pulse widths >1000¬µsecor <500 ¬µS 
‚Ä¢ Number of patients who achieved ‚â• 50% pain relief during the trial (from either arm)  
‚Ä¢ Rate of device- related and/or procedure -related AEs from Trial Lead 
implant through study completion. 
 
DRAFT   CONFIDENTIAL  
  [ADDRESS_57949] been incorporated into the study to minimize potential bias.  
‚Ä¢ Subjects will be screened to confirm eligibility for enrollment with defined inclusion/exclusion criteria prior to enrollment  
‚Ä¢ Subject demographics will be collected at baseline on possible differences that may affect the primary objective  
‚Ä¢ All study clinicians, participating site personnel, and the Sponsor‚Äôs personnel will be trained on their respective aspects of the study using standardized training materials  
‚Ä¢ All study clinicians w ill be trained on and required to follow the CIP 
DRAFT   CONFIDENTIAL  
  [ADDRESS_57950] meet the 
following criteria:  
‚Ä¢ Curriculum vitae (CV) providing evidence of sufficient training and 
experience in the management of patients with chronic pain. 
‚Ä¢ Has implanted and managed at least [ADDRESS_57951] 12 months. 
‚Ä¢ The Investigator‚Äôs participation in other clinical studies will not present a conflict of interest and will not interfere with the clinical study enrollment, 
study management, or study confidentiality. 
‚Ä¢ Is willing to provide any conflicts of interest details.  
‚Ä¢ Is willing to comply with all federal laws and regulations as well as IRB rules rega rding clinical studies.  
 
DRAFT   CONFIDENTIAL  
  16 8.0 STUDY POPULATION   
Subjects that are candidates for SCS, agreed to undergo an SCS temporary trial and 
that meet study eligibility criteria will be asked to participate in the study and will be required to sign informed consent prior  to any study -related procedures or data 
collection occurring. It is expected that up to 15 subjects may be enrolled to screen for eligibility, and up to 10 subjects will undergo an SCS trial with the Algovita¬Æ Trial System. Subjects may either be male or female and must meet all eligibility 
criteria noted below which are typi[INVESTIGATOR_54192]-market studies.  
 
8.[ADDRESS_57952] : 
1. be eligible for SCS therapy according to the Algovita¬Æ SCS system 
Indications for Use statement 
2. be undergoing a SCS trial using Algovita¬Æ SCS system 
3. sign a valid, Institutional Review Board (IRB) -approved informed consent 
form.  
4. be [ADDRESS_57953] NOT : 
 
1. be contraindicated for an Algovita¬Æ SCS system 
2. have a cognitive impairment or exhibits any characteristic, that would limit the study candidate's ability to assess pain relief or complete study 
assessments 
3. have a life expectancy of less than [ADDRESS_57954] data will be collected and documented on case report forms (CRFs). 
Drafts of the CRFs for this study are located in Appendix 17. 
 
9.1.[ADDRESS_57955] agreed to 
undergo an SCS temporary trial and that meet study eligibility. Subjects who meet these criteria  will be  asked to participate in the study and if they 
agree  will be required to sign an informed consent prior to any study -
related procedures or data collection occurring . 
 
 
Assessments and Data Collection  
Enrollment  
Baseline  
After Implant  
Follow -up Visits  
Study Exit  
‚Ä¢ Eligibility 
 ‚úì     
‚Ä¢ Medical history  
‚Ä¢ Physical exam  ‚úì     
‚Ä¢ Informed c onsent  ‚úì     
‚Ä¢ Record demographics  
‚Ä¢ Brief Pain Inventory 
‚Ä¢ Record pain map   ‚úì 
‚úì 
‚úì   
 
‚úì  
 
‚úì 
‚Ä¢ Implant and s ystem information    ‚úì   
‚Ä¢ Record pain rating for current arm  
‚Ä¢ Record paresthesia and pain map for 
current arm  
‚Ä¢ Document any AEs     
 
 
‚úì ‚úì ‚úì 
‚Ä¢ Record subject program preference  
‚Ä¢ Record subject satisfaction and pain 
relief from each program  
‚Ä¢ Document study exit reason & any 
     ‚úì 
‚úì 
 
‚úì 
Table 6 -1: Summary of assessments at each visit 
 
9.1.[ADDRESS_57956]‚Äôs (or their legally authorized representative or 
guardian) voluntary agreement to participate in a particular clinical 
DRAFT   CONFIDENTIAL  
  [ADDRESS_57957]‚Äôs decisio n to 
participate. When a subject signs and dates the informed consent form, 
he/she is considered a subject enrolled in the study. Prior to initiation of any study -specific procedures, subjects (or their 
legally authorized representative or guardian) must sign and date the informed consent form and Health Insurance Portability and Accountability Act (HIPAA) authorization, or equivalent, where required by [CONTACT_54221]. Documentation that consent was obtained prior to any study- related procedures must be maintained in the subject‚Äôs case history.  
 
9.1.[ADDRESS_57958] ‚Äôs eligibility for study participation and perform a Baseline visit. 
The following data will be collected by [CONTACT_54222]:  
‚Ä¢ Relevant medical history (including diagnosis, prior treatment for chronic 
pain, past surgical procedures) 
‚Ä¢ Demographics  
‚Ä¢ Physical examination  
‚Ä¢ Collection of Brie f Pain Inventory, pain- related ratings (NRS) and pain map  
 
9.1.[ADDRESS_57959] as necessary with 
the Algovita¬Æ  Trial Lead implant. The recommended placement for the device 
will be determined by [CONTACT_54223]. Information regarding the devices used, location, and procedure data will be collected on an Implant CRF. A Nuvectra¬Æ  representative may be present during the implant 
procedure and may assist in the programming of the Algovita¬Æ system at the 
Investigator‚Äôs direction.  
9.1.5 FOLLOW -UP VISITS  
Follow- up visits will occur at day 4 and 7 (+/ ‚Äì2) post -implantation. Data 
collected at these visits will be recorded on case forms (CRFs) and will include: 
‚Ä¢ Record paresthesia and pain map for current arm   
‚Ä¢ Record pain rating for current arm 
‚Ä¢ Document AEs 
‚Ä¢ Program subject with next arm parameters and document  
9.1.[ADDRESS_57960] who signed an informed consent form, as they are considered enrolled in the study. Data to be c ollected 
at this visit includes:  
‚Ä¢ Record paresthesia and pain map for current arm  
‚Ä¢ Record pain rating for current arm  
‚Ä¢ Record program preference  
DRAFT   CONFIDENTIAL  
  19 ‚Ä¢ Record satisfaction and pain relief from each program  
‚Ä¢ Study exit date and reason for study exit  
Additional data that will be collected as they occur include: 
‚Ä¢ Device or procedure related AEs  
‚Ä¢ Technical Observations/Device Deficiencies  
‚Ä¢ Surgical Interventions  
The following scenarios may lead to study exit and will require completion of a 
Study Exit CRF.  
‚Ä¢ Inclusion/exclus ion criteria not met  
‚Ä¢ Subject ineligibility for implant, in the opi[INVESTIGATOR_9764]  
‚Ä¢ SCS lead removal without re -implantation  
‚Ä¢ Implant attempted, however no SCS was implanted  
‚Ä¢ Voluntary withdrawal by [CONTACT_1130]  
‚Ä¢ Investigator chooses to withdraw a subject 
‚Ä¢ Failure to maintain adequate study compliance  
‚Ä¢ Subject Death  
  
DRAFT   CONFIDENTIAL  
  20  
10.0 ADVERSE EVENT REPORTING  
10.1 ADVERSE EVENTS  
At each evaluation, the investigator will determine whether any adverse events 
(AE‚Äôs) have occurred.  For the purpose of this protocol, an adverse event  is any 
undesirable clinical occurrence in a subject that can be attributed to the device or incision closure procedure.  In this study, patients should be encouraged to report AE‚Äôs spontaneously or in response to general, non -directed questioning (e.g., ‚ÄúHow has your health been 
since the last visit?‚Äù).  Any time during the study, the patient may volunteer information that resembles an AE.  If it is determined that an AE has occurred, the investigator should obtain all the information required to complete the AE Form of the CRF.  
 
The following categories of  adverse event severity are to be used:  
Mild  Awareness of a sign or symptom that does not interfere with the 
patient's usual activity or is transient, resolved without treatment and 
with no sequelae  
Moderate  Interferes with the patient's usual activity  
Severe  Any fatal or immediately life -threatening clinical experience that 
requires a subject to be hospi[INVESTIGATOR_057], or hospi[INVESTIGATOR_54193].  This includes events that cause 
fetal distress, fetal death, congenital abnormality or malignancy or 
any permanently disabling event.  
 
10.[ADDRESS_57961] been identified as possible 
complications of implanting neurostimulator  leads . 
‚Ä¢ Infection at implant site  
‚Ä¢ Pain at implant site  
‚Ä¢ Bleeding  
‚Ä¢ Bruising  
‚Ä¢ Device failure  
o Unintended stimulation  
o Increased stimulation  
o Decreased stimulation  
o Lead breakage /migration  
o Battery depletion  
o Erosion of device 
o General device failure  
 
DRAFT   CONFIDENTIAL  
  [ADDRESS_57962], problem, or death was not previously identified in 
nature, severity or degree of incidence in the investigational plan or application 
(including a supplementary plan or application),  or any other unanticipated serious 
problem associated with a device that relates to the rights, safety or welfare of 
subjects.  
For the purposes of this study, serious is defined as any significant adverse 
experience, including those which may be either li fe-threatening or involve 
permanent or long term injuries, but excluding injuries that are non- life-threatening 
and that are temporary and reasonably reversible.  
An Investigator must submit to the sponsor and to the responsible Medical 
Ethics Committee ( I RB ) any unanticipated adverse device effects occurring 
during the study as soon as possible, but in no event later than ten (10) working 
days after the Investigator first learns of the effect.  
Contact [CONTACT_5627]:  
Erin Dewenter, RN                          
Ohio Pain Clinic   
[ADDRESS_57963]  
Dayton, OH [ZIP_CODE] 
 
Report  Submit To  Description/Constraints  
Death  Sponsor  Submit as soon as possible but no later than [ADDRESS_57964] 
(UADE) [ADDRESS_57965] learns of the event, or per 
local reporting requirements, whichever is more 
conservative.  
Other Adverse Device 
Effects  Sponsor  Submit or report as required per local reporting 
requirements.  
IRB Submit or report as required per local IRB reporting 
requirements.  
Regulatory Body  Submit or report as required per regulations.  
Table 11 -1: Investigator adverse event reports  
DRAFT   CONFIDENTIAL  
  22 11.0 STATISTICS  
11.1 Study Population  
All patients who received treatment will be included in an intent- to-treat (ITT) 
analysis.  A per protocol analysis will also be conducted if there are protocol 
violators. 
11.2 Safety Analysis 
All patients who received treatment will be included in the safety analysis.  The 
proportion of patients with complications will be compared by [CONTACT_3493]‚Äôs Exact test. 
The two treatment groups will be compared using t -test for continuous variables 
and chi square test for category variables. All adverse events will be listed and the frequencies, severity, and relationship to the treatment procedure wi ll be tabulated 
and compared by [CONTACT_6660]
.  
DRAFT   CONFIDENTIAL  
  23 12.0 ETHICS  
12.1 Medical Ethics Committee (  IRB ) Review 
Prior to initiation of the study, the Principal Investigator [INVESTIGATOR_54194], sample Informed Consent Form, and any other documents that may be  
requested, to the IRB for review and approval.  The Principal Investigator [INVESTIGATOR_54195] s tudy.   If the IRB imposes any additional requirements (e.g. safety reports, 
progress reports etc.), the Sponsor will prepare the required documents and send them to the Investigator for reporting to the IRB. 
12.[ADDRESS_57966] of the Study  
This study will be conducted in compliance with the protocol, good clinical 
practices (GCP), and the applicable regulatory requirements.  
12.3 Patient Information and Consent  
Prior to screening for the study, each patient, as required, will be informed in detail 
about the nature of the clinical investigation with its expected risks and discomforts.  
The basic elements of informed consent as specified by [CONTACT_54224] 
2001/20/EC will be followed.  Written consent will be obtained from each patient 
as required, to be involved in the clinical study by [CONTACT_54225] -approved 
Informed Consent Form.  The Principal Investigator [INVESTIGATOR_54196].  
Each patient will be g iven a copy of the Informed Consent Form.  The patients will 
also be instructed that they are free to withdraw their consent and discontinue their 
participation in the study at any time without prejudice.  Prior to the start of the 
study, the Principal Investigator [INVESTIGATOR_54197].  At the conclusion of the 
study, the Principal Invest igator will provide a letter to  stating that a signed 
informed consent was obtained from each of the study patients.  The signed 
informed consent forms will be kept on file at the study site for the required period 
of time.  
DRAFT   CONFIDENTIAL  
  [ADDRESS_57967] be met by [CONTACT_1268] [INVESTIGATOR_54198].  Compliance will be confirmed by [CONTACT_54226]-study visit.  The pre- investigational requirements may include:  
1. Current Curricula Vitae and current medical licenses or medical numbers of the Prin cipal 
Investigator and all sub -investigators 
2.  IRB  name [CONTACT_3816]; Department of Health and Human Services (DHHS) number, if 
applicable, or membership list  
3. Written documentation of  IRB  approval of protocol (identified by [CONTACT_54227]) and informed consent document (identified by [CONTACT_54228]) 
4. A copy of the  IRB  approved consent form (that has also been approved by   ) 
5. A signed Clinical Research Agreement ‚Ä¢ Provisions for direct access to source/data documents if necessary for st udy-related 
monitoring, audits,  IRB  review, and regulatory inspection. 
13.[ADDRESS_57968] of the clinical supplies returned.  Under no circumstances will the Principal Investigator [INVESTIGATOR_54199].  
13.3 Case Report Forms (CRFs)  
   will provide the CRFs.  The Principal Investigator [INVESTIGATOR_54200], 
completeness, and accuracy of the information on the CRF.  All entries m ust be legibly 
recorded in ink, with entry errors designated by a single- line cross out, initialed and dated, 
such that the original entry remains readable  
The Principal Investigator [INVESTIGATOR_54201]. 
The Principal Investigator [INVESTIGATOR_54202] a file copy of each completed CRF.  In addition, the 
Principal Investigator [INVESTIGATOR_54203](s) have access to source 
DRAFT   CONFIDENTIAL  
  25 documents (e.g., hospi[INVESTIGATOR_54204]) to ensure accuracy and completeness of the 
CRFs during the periodic reviews. 
13.4 Study Completion  
Data and materials that are required before the study can be considered complete and/or 
terminated are:  
‚Ä¢ Laboratory findings, clinical data, and all special test results from treatment through 
the end of the follow-up period 
‚Ä¢ CRFs (including correction forms) properly completed by [CONTACT_54229] 
‚Ä¢ Completed Device Accountability Records  
‚Ä¢ Statement of outcome for each unanticipated adverse device effect reported  
‚Ä¢ Copi[INVESTIGATOR_54205] (if applicable)  
13.5 Final Report  
The purpose of this single center pi[INVESTIGATOR_54206]. The results will be presented in a 
clinical report presented by    [CONTACT_54230] (PI).   
13.[ADDRESS_57969] for the latter of a period of 2 
years following the approval of a premarket  application (U.S.) or [ADDRESS_57970] 
parties other than those noted below is prohibited. 
At the patient's request, medical information may be given to his or her personal physician 
or other appropriate medical personnel responsible for his or her welfare.  
Data generated by [CONTACT_54231], and the IRB s (if appropriate).   
The information obtained in this study may be published in medical journals, but will not 
reveal the id entity of the individual patients.  
DRAFT   CONFIDENTIAL  
  [ADDRESS_57971] the investigation in accordance with the conditions 
imposed by [CONTACT_54232] /IRB .  This includes the supervision of the device involving 
human patients and ensuring that the requirements for obtaining informed consent are met.  
 
 
   
Principal Investigator        [INVESTIGATOR_54207]  
  [ADDRESS_57972], Republic of South Africa, October 1996 
and the 52nd WMA General Assembly, Edinburgh, Scotland, October 2000  
  
1. INTRODUCTION  
1. The World Medical Association has developed the Declaration of Helsinki as a statement of ethical principles 
to provide guid ance to physicians and other participants in medical research involving human subjects. Medical 
research involving human subjects includes research on identifiable human material or identifiable data.  
2. It is the duty of the physician to promote and safeguar d the health of the people. The physician's knowledge and 
conscience are dedicated to the fulfillment of this duty.  
3. The Declaration of Geneva of the World Medical Association binds the physician with the words, "The health 
of my patient will be my first co nsideration," and the International Code of Medical Ethics declares that, "A 
physician shall act only in the patient's interest when providing medical care which might have the effect of 
weakening the physical and mental condition of the patient."  
4. Medical  progress is based on research which ultimately must rest in part on experimentation involving human 
subjects.  
5. In medical research on human subjects, considerations related to the well -being of the human subject should take 
precedence over the interests of  science and society.  
6. The primary purpose of medical research involving human subjects is to improve prophylactic, diagnostic and 
therapeutic procedures and the understanding of the aetiology and pathogenesis of disease. Even the best proven 
prophylactic, diagnostic, and therapeutic methods must continuously be challenged through research for their 
effectiveness, efficiency, accessibility and quality.  
7. In current medical practice and in medical research, most prophylactic, diagnostic and therapeutic procedu res 
involve risks and burdens.  
8. Medical research is subject to ethical standards that promote respect for all human beings and protect their health 
and rights. Some research populations are vulnerable and need special protection. The particular needs of the 
economically and medically dis advantaged must be recognized. Special attention is also required for those who 
cannot give or refuse consent for themselves, for those who may be subject to giving consent under duress, for 
those who will not benefit personally from the research and for t hose for whom the research is combined with 
care.  
9. Research Investigators should be aware of the ethical, legal and regulatory requirements for research on human 
subjects in their own countries as well as applicable international requirements. No national ethical, legal or 
regulatory requirement should be allowed to reduce or eliminate any of the protections for human subjects set 
forth in this Declaration.  
2. BASIC PRINCIPLES FOR ALL MEDICAL RESEARCH  
DRAFT   CONFIDENTIAL  
  [ADDRESS_57973], the confidentiality of the patient's information and to minimize the 
impact of the study on the subject's physical and mental integrity and on the personality of the subject.  
13. In any research on human beings, each potential subject must be adequa tely informed of the aims, methods, 
sources of funding, any possible conflicts of interest, institutional affiliations of the researcher, the anticipated 
benefits and potential risks of the study and the discomfort it may entail. The subject should be info rmed of the 
right to abstain from participation in the study or to withdraw consent to participate at any time without reprisal. 
After ensuring that the subject has understood the information, the physician should then obtain the subject's 
freely -given inf ormed consent, preferably in writing. If the consent cannot be obtained in writing, the non -written 
consent must be formally documented and witnessed.  
DRAFT   CONFIDENTIAL  
  [ADDRESS_57974] obtain that assent in addition to the consent of the legally 
authorized representative.  
17. Research o n individuals from whom it is not possible to obtain consent, including proxy or advance consent, 
should be done only if the physical/mental condition that prevents obtaining informed consent is a necessary 
characteristic of the research population. The sp ecific reasons for involving research subjects with a condition 
that renders them unable to give informed consent should be stated in the experimental protocol for consideration 
and approval of the review committee. The protocol should state that consent t o remain in the research should 
be obtained as soon as possible from the individual or a legally authorized surrogate.  
18. Both authors and publishers have ethical obligations. In publication of the results of research, the investigators 
are obliged to preserv e the accuracy of the results. Negative as well as positive results should be published or 
otherwise publicly available. Sources of funding, institutional affiliations and any possible conflicts of interest 
should be declared in the publication. Reports of  experimentation not in accordance with the principles laid down 
in this Declaration should not be accepted for publication.  
3. ADDITIONAL PRINCIPLES FOR MEDICAL RESEARCH COMBINED WITH MEDICAL CARE  
1. The physician may combine medical research with medical care , only to the extent that the research is justified 
by [CONTACT_54233], diagnostic or therapeutic value. When medical research is combined with medical 
care, additional standards apply to protect the patients who are research subjects.  
2. The benef its, risks, burdens and effectiveness of a new method should be tested against those of the best current 
prophylactic, diagnostic, and therapeutic methods. This does not exclude the use of placebo, or no treatment, in 
studies where no proven prophylactic, diagnostic or therapeutic method exists.  
3. At the conclusion of the study, every patient entered into the study should be assured of access to the best proven 
prophylactic, diagnostic and therapeutic methods identified by [CONTACT_1758].  
4. The physician should fu lly inform the patient which aspects of the care are related to the research. The refusal 
of a patient to participate in a study must never interfere with the patient -physician relationship.  
5. In the treatment of a patient, where proven prophylactic, diagnos tic and therapeutic methods do not exist or have 
been ineffective, the physician, with informed consent from the patient, must be free to use unproven or new 
prophylactic, diagnostic and therapeutic measures, if in the physician's judgment it offers hope of saving life, re -
establishing health or alleviating suffering. Where possible, these measures should be made the object of 
research, designed to evaluate their safety and efficacy. In all cases, new information should be recorded and, 
where appropriate, p ublished. The other relevant guidelines of this Declaration should be followed.  
 
DRAFT   CONFIDENTIAL  
  31 16.0 REFERENCES BIBLIOGRAPHY  
 
i American Chronic Pain Association Resource Guide to Chronic Pain Medication 
and Treatment, 2014 Edition.  
ii North RB. Failed back surgery syndrome: 5 -year follow -up in 102 patients 
undergoing repeated operation. Neurosurgery, vol. 28, p. 685‚Äì90, 1991.  
iii Wilkinson HA. The Failed Back Surgery Syndrome: Etiology and Therapy, 2nd 
edition., Philadelphia: Harper & Row, 1991.  
iv Law JD. Reoperation after lumbar intervertebral disc surgery. J Neurosurg, vol. 
48, p. 259‚Äì63, 1978.  
v  Lehmann TR. Repeat lumbar surgery: A review of patients with failure from 
previous lumbar surgery treated by [CONTACT_15209][INVESTIGATOR_54208]. Spi[INVESTIGATOR_050] , vol. 6, p. 615‚Äì9, 1981.  
vi Jobling DT, Tallis RC, Sedgwick EM, Illis LS. Electronic aspects of spi[INVESTIGATOR_1304] -cord 
stimulation in multiple sclerosis. Med Biol Eng Comput 1980; 18:[ADDRESS_57975] Neurophysiol 1981; 44:160- 170.  
viii Meyerson B. Commentary on: Holsheimer J. Effectiveness of spi[INVESTIGATOR_54209]: Analysis of technical drawbacks and solutions. Neurosurgery 1997; 40:990- 999.  
ix Gould B, Bradley K. Pulse width programming in spi[INVESTIGATOR_54210]. 
Abstract of the American Academy of Pain Medicine 22nd Annual Meeting,  [ADDRESS_57976] Stimulation: A Clinical Study. Pain Physician 2010; 13:[ADDRESS_57977] stimulation: a mathematical modeling study. 
Med Biol Eng Comput (2011) 49:765‚Äì[ADDRESS_57978] of stimulus pulse duration on 
selectivity of neural stimulation. IEEE Trans Biomed Eng 1996; 43:161 ‚Äì166.                                            